Genenta Science S.p.A.

Genenta Science S.p.A. announced it will operate under the business name Saentra Forge and its Nasdaq ticker symbol will change from GNTA to SAEN, effective November 4, 2026. This rebranding aligns with the company's strategic transformation into an industrial consolidator focused on security-regulated sectors including aerospace, defense, national security, biotechnology, and biosecurity. The company's legal name and corporate structure remain unchanged, and no action is required from shareholders.

Genenta Science S.p.A. held an Extraordinary Shareholders’ Meeting where shareholders approved significant corporate actions. The Board was granted authority to increase share capital by up to €300,000,000 and issue up to 120,000,000 new ordinary shares or convertible bonds. Additionally, shareholders authorized a reverse stock split at a ratio between 1-for-10 and 1-for-20, intended to help maintain Nasdaq's minimum bid price requirement. A proposal to change the company's corporate name was deferred to a reconvened meeting on September 10, 2026, for further evaluation.

Genenta Science S.p.A.'s backed company, Sòphia High Tech S.r.l., announced the unveiling of ROMAN, a robotic arm engineered for inspection and maintenance operations inside nuclear fusion machines. This development marks Sòphia HT's entry into the nuclear domain, leveraging its precision engineering capabilities for hazardous environments. The project aligns with Genenta's strategy to build an industrial platform across national security-related sectors, with Genenta holding a 19% equity interest and an option to increase ownership to 51% in Sòphia HT.

Genenta Science S.p.A. announced strong financial results for its investee, Sòphia High Tech S.r.l., for the fiscal year ended December 31, 2025. Sòphia HT reported a 29.3% increase in sales to €7.17 million and a 68.1% rise in EBITDA to €1.61 million, driven by higher sales, increased operating income, and disciplined cost management. Genenta, which owns approximately 19% of Sòphia HT, is evolving into Saentra Forge, focusing on aerospace, defense, biotech, and national security technologies. Sòphia HT also appointed a new Board of Directors to guide its industrial scale-up and international expansion.

The Court of Milan ruled in favor of Genenta Science, determining that the company's interest in maintaining the effectiveness of an amendment to its corporate purpose outweighed the alleged prejudice asserted by plaintiffs. As a result, the amendment is now fully effective, and a previously issued suspension order has been removed from the Italian Companies Register. The underlying civil action challenging the validity of shareholder resolutions from May 2, 2024, and October 29, 2025, remains pending, and Genenta Science plans to vigorously defend these resolutions.

Genenta Science S.p.A. announced the completion of its acquisition of a majority equity ownership in Sòphia High Tech S.r.l., following the satisfaction of all closing conditions, including Italian 'Golden Power' authorization. The company also reported the appointment of new directors to its Board. Additionally, an Extraordinary Shareholders' Meeting, which included proposals for a corporate name change and share capital increase, was adjourned to July 29, 2026, to allow for further shareholder engagement.

Genenta Science S.p.A. announced that the Court of Milan issued an interim order in a proceeding initiated by minority shareholders. The Court denied the request to suspend the multiple voting rights mechanism, which remains in effect. However, the Court granted the request to suspend the resolution amending the company's corporate purpose, citing concerns about its breadth. Genenta Science has appealed the suspension of the corporate purpose resolution, with a hearing scheduled for July 9, 2026.

Genenta Science S.p.A. filed a Form 6-K detailing two agreements with Pierluigi Paracchi, both dated June 19, 2026. These include a Parachute Agreement, which typically outlines severance terms, and an amendment to a non-compete covenant. The filing incorporates the full text of these agreements by reference.

Genenta Science S.p.A. announced it has regained compliance with Nasdaq's minimum bid price requirement. The company received a letter from Nasdaq confirming that its American Depositary Shares (ADSs) maintained a closing bid price of $1.00 or more for 10 consecutive business days from June 1 to June 12, 2026. This resolves the previous non-compliance notification issued on April 10, 2026.

Genenta Science S.p.A. completed the acquisition of the remaining 80.5% equity ownership in A.T.C. S.r.l. for an aggregate purchase price of Euro 9,604,076.82. The payment was made by setting off the amount owed by A.T.C. Shareholders for subscribing to 24,625,838 ordinary shares of Genenta Science at Euro 0.39 per share. The acquired shares are subject to a 36-month lock-up period, and the agreement includes both put and call options for the shares.